Send mail to Author

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors (Article)

Please indicate your contact information and select, which author you want to contact.



 
  _  _      ___      _____    __   __    ______   __   __  
 | \| ||   / _ \\   |__  //   \ \\/ //  /_   _//  \ \\/ // 
 |  ' ||  / //\ \\    / //     \ ` //     | ||     \ ` //  
 | .  || |  ___  ||  / //__     | ||     _| ||      | ||   
 |_|\_|| |_||  |_|| /_____||    |_||    /__//       |_||   
 `-` -`  `-`   `-`  `-----`     `-`'    `--`        `-`'
 


Back to frontdoor view

OPUS4 Logo